Protein Kinase Inhibitors Concept

subject area of

• 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  Journal Articles
• 4-phenylbutyrate and valproate treatment attenuates the progression of atherosclerosis and stabilizes existing plaques  Journal Articles
• 8-isoprostaglandin E2 activates Ca2+-dependent K+ current via cyclic AMP signaling pathway in murine renal artery  Journal Articles
• BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase  Journal Articles
• A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer  Journal Articles
• A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177  Journal Articles
• A Small Molecule Discrimination Map of the Antibiotic Resistance Kinome  Journal Articles
• A lentiviral vector‐based insertional mutagenesis screen identifies mechanisms of resistance to MAPK inhibitors in melanoma  Journal Articles
• A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication  Journal Articles
• A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group  Journal Articles
• A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191  Journal Articles
• A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer  Journal Articles
• A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer  Journal Articles
• A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group  Journal Articles
• A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium  Journal Articles
• A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium  Journal Articles
• A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors  Journal Articles
• A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study  Journal Articles
• A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer  Journal Articles
• A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients  Journal Articles
• ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis  Journal Articles
• Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance  Journal Articles
• Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis  Journal Articles
• Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma  Journal Articles
• Akt isoform specific effects in ovarian cancer progression  Journal Articles
• Allosteric linkers in cAMP signalling  Journal Articles
• An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma  Journal Articles
• An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy  Journal Articles
• Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data  Journal Articles
• Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis  Conferences
• Bacterial Peptidoglycan Stimulates Adipocyte Lipolysis via NOD1  Journal Articles
• Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck  Journal Articles
• Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration  Journal Articles
• Bruton’s tyrosine kinase (BTK) inhibitors alter blood glucose and insulin in obese mice but reduce inflammation independent of BTK  Journal Articles
• Bruton’s tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation  Journal Articles
• CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor–based regimen versus a cni-based regimen: a systematic review and meta-analysis of randomized, controlled trials  Journal Articles
• Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium  Journal Articles
• Canadian Consensus Recommendations on the Management of MET-Altered NSCLC  Journal Articles
• Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas  Journal Articles
• Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer  Journal Articles
• Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era  Journal Articles
• Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy  Journal Articles
• Cardiovascular Safety Of Nintedanib In Subgroups By Cardiovascular Risk At Baseline In The Tomorrow And Inpulsis Trials  Conferences
• Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?  Journal Articles
• Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance  Journal Articles
• Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System  Journal Articles
• Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study  Journal Articles
• Checkpoint inhibitor-associated autoimmunity  Journal Articles
• Chronic opioids regulate K_ATP channel subunit Kir6.2 and carbonic anhydrase I and II expression in rat adrenal chromaffin cells via HIF-2α and protein kinase A  Journal Articles
• Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)  Journal Articles
• Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients  Journal Articles
• Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase  Journal Articles
• Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China  Journal Articles
• Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective  Journal Articles
• Current Incidence and Outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Stromal Tumors  Journal Articles
• Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial  Journal Articles
• Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib  Journal Articles
• Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis  Journal Articles
• Determination of soluble CAMP-dependent protein kinase activity in guinea-pig tracheal smooth muscle  Journal Articles
• Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors  Journal Articles
• EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP)  Journal Articles
• Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer  Journal Articles
• Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial  Journal Articles
• Effects of PKB/Akt inhibitors on insulin-stimulated lipogenesis and phosphorylation state of lipogenic enzymes in white adipose tissue  Journal Articles
• Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis  Journal Articles
• Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline  Journal Articles
• Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome  Journal Articles
• Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol  Journal Articles
• Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy  Journal Articles
• Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study  Journal Articles
• Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer  Journal Articles
• Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice  Journal Articles
• Gender and BCR‐ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia  Journal Articles
• Glycosyltransferases and Glycosaminoglycans in Bleomycin and Transforming Growth Factor-β1–Induced Pulmonary Fibrosis  Journal Articles
• Guanosine Protects Glial Cells Against 6-Hydroxydopamine Toxicity  Journal Articles
• High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells  Journal Articles
• Hyperosmotic stress induces Rho/Rho kinase/LIM kinase-mediated cofilin phosphorylation in tubular cells: key role in the osmotically triggered F-actin response  Journal Articles
• Hypoxia-Induced Lactate Dehydrogenase Expression and Tumor Angiogenesis  Journal Articles
• Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors  Journal Articles
• Inhibition of Aminoglycoside Antibiotic Resistance Enzymes by Protein Kinase Inhibitors  Journal Articles
• Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial  Journal Articles
• Inhibition of sporulation, glycopeptide antibiotic production and resistance in Streptomyces toyocaensis NRRL 15009 by protein kinase inhibitors  Journal Articles
• Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin  Journal Articles
• Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.  Journal Articles
• Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors  Journal Articles
• Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin  Journal Articles
• Kinase inhibitors modulate huntingtin cell localization and toxicity  Journal Articles
• Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience  Journal Articles
• Low salt concentrations activate AMP-activated protein kinase in mouse macula densa cells  Journal Articles
• Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis  Journal Articles
• Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3This paper is one of a selection of papers published in this Special Issue, entitled Young Investigator's Forum.  Conferences
• Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia  Journal Articles
• Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators  Journal Articles
• Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer  Journal Articles
• Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition  Journal Articles
• Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)  Journal Articles
• Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases  Journal Articles
• Nintedanib in Progressive Fibrosing Interstitial Lung Diseases  Journal Articles
• Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial  Journal Articles
• Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial  Journal Articles
• Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance  Journal Articles
• Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial  Journal Articles
• Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review  Journal Articles
• Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer  Journal Articles
• Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts  Journal Articles
• Outcomes of children with chronic myeloid leukemia: A population‐based cohort study  Journal Articles
• Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC  Journal Articles
• PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia  Journal Articles
• PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma  Journal Articles
• PKC-β1 Mediates Glucose-Induced Akt Activation and TGF-β1 Upregulation in Mesangial Cells  Journal Articles
• PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer  Journal Articles
• Panax quinquefolium saponin combined with dual antiplatelet drugs inhibits platelet adhesion to injured HUVECs via PI3K/AKT and COX pathways  Journal Articles
• Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children  Journal Articles
• Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors  Journal Articles
• Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies  Journal Articles
• Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma  Conferences
• Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)  Journal Articles
• Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice  Journal Articles
• Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors  Journal Articles
• Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives  Journal Articles
• Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases  Journal Articles
• Predicting response to EGFR-tyrosine kinase inhibitors among diverse ancestries: Just way too polymorphic  Journal Articles
• Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib  Journal Articles
• Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor  Journal Articles
• Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies  Journal Articles
• Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations  Journal Articles
• Protein kinase R-like endoplasmic reticulum kinase and glycogen synthase kinase-3α/β regulate foam cell formation  Journal Articles
• Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma  Journal Articles
• Quizartinib for the treatment of acute myeloid leukemia  Journal Articles
• RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice  Journal Articles
• Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520  Journal Articles
• Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma  Journal Articles
• Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo  Journal Articles
• Real-time fluorogenic kinase assay using protein as substrate  Journal Articles
• Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M  Journal Articles
• Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer.  Journal Articles
• Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’  Journal Articles
• Reversible Cabozantinib-Induced Cardiomyopathy  Journal Articles
• Role of α-Helical Coiled-coil Interactions in Receptor Dimerization, Signaling, and Adaptation during Bacterial Chemotaxis  Journal Articles
• Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma  Journal Articles
• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America  Journal Articles
• Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors  Journal Articles
• Severe Bronchorrhea in a Patient with Bronchioloalveolar Carcinoma  Journal Articles
• Simultaneous Inhibition Assay for Human and Microbial Kinases via MALDI‐MS/MS  Journal Articles
• Sirolimus and mTORC1: centre stage in the story of what makes muscles bigger?  Journal Articles
• Skeletal muscle metabolism is unaffected by DCA infusion and hyperoxia after onset of intense aerobic exercise  Journal Articles
• Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)  Journal Articles
• Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study  Conferences
• Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance  Journal Articles
• Superoxide anion mediates angiotensin II-induced potentiation of contractile response to sympathetic stimulation  Journal Articles
• Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results  Journal Articles
• Synthesis and Biological Activity of a Focused Library of Mitogen‐activated Protein Kinase Phosphatase Inhibitors  Journal Articles
• Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma  Journal Articles
• Targeted therapy for metastatic renal cell carcinoma  Journal Articles
• Targeting the epidermal growth factor receptor in non-small-cell lung cancer: Who, which, when, and how?  Journal Articles
• The Antibiotic Resistome: A Guide for the Discovery of Natural Products as Antimicrobial Agents  Journal Articles
• The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group  Journal Articles
• The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)  Journal Articles
• The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis  Journal Articles
• The inhibition of endocytosis affects HDL-lipid uptake mediated by the human scavenger receptor class B type I  Journal Articles
• The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis  Journal Articles
• Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia  Journal Articles
• Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials  Journal Articles
• Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline  Journal Articles
• Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update  Journal Articles
• Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?  Journal Articles
• Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update  Journal Articles
• Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?  Journal Articles
• Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review  Journal Articles
• Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease  Journal Articles
• Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia  Journal Articles
• Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis  Journal Articles
• Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor of Bone  Journal Articles
• Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. - PubMed - NCBI  Other
• β2 integrin–derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis  Journal Articles